Navigation Links
Cardio Vascular Medical Device Sends Update to Shareholders
Date:10/26/2009

HAIFA, Israel, October 26 /PRNewswire-FirstCall/ -- Cardio Vascular Medical Device Corp. (OTC: CVSL), a leading developer of advanced cardiovascular surgery technology, today released a brief shareholders update.

Cardio Vascular Medical Device holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.

The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers.

"Cardio Vascular Medical Device has developed a technology that provides several advantages over the current guidewires being employed in angioplasty procedures," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. "And with well over 7 million angioplasties performed each year, the global annual potential addressable market in excess of $500 million."

Cardio Vascular Medical Device is working diligently to complete the development of the guidewire, in preparation for full commercial distribution.

Cardio Vascular Medical Device Corp. plans to keep public shareholders informed of all upcoming company developments.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated in the forward-looking statements. Cardio Vascular Medical Device Corp. public filings may be viewed at http://www.sec.gov.

    Contact: Alex Traiman, Media Relations, +1-646-863-9729;
    Asher Zwebner, +972-54-464-6363, asher@fxmng.com



SOURCE Cardio Vascular Medical Device Corp.


'/>"/>
SOURCE Cardio Vascular Medical Device Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
7. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
8. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
9. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
10. Cardiologists Tackle Next Frontier in Cardiovascular Disease
11. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... TORONTO , Sept. 6, 2017 /PRNewswire/ ... new knowledge and skills while treating their ... for hands-on experience without involving patients. Simulation ... skills. Clinicians can carry out procedures, refine ... at risk. Integration of new technology, such ...
(Date:9/5/2017)... KEYSTONE, Colo. , Sept. 5, 2017 ... their XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party ... update existing CT scanners and allows compliance with current ... The Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically ... notifications and alerts of potential radiation doses over a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... Spain’s popular line ... Laboratories, is coming soon to RonnieColemanNutrition.com. , ACPG Laboratories has been in ... trusted, well-respected brand reliant on the healing properties of plants, a proven science ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... to serve as strategic adviser to the animal healthcare division of Sonoma ... Bridge Animal Referral Center (BARC) in Edmonds, Washington, which specializes in compassionate ...
(Date:9/19/2017)... ... , ... Premiere Long Island dental office Gold Coast Smiles is pleased to ... dentists in America under age 40 by Incisal Edge magazine. , Incisal Edge ... the best 40 dentists under the age of 40 renowned for medical innovations and ...
(Date:9/19/2017)... ... September 19, 2017 , ... When it comes to household ... deserve clear instructions on how to keep babies and toddlers safe, and there's no ... Safety Month. , Great Time to Check Labels, Brands that sell all kinds of ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency ... the Certified Emergency Nurse (CEN®) certification according to a large-scale study ... of certification study, conducted by the Human Resources Research Organization (HumRRO) in late ...
Breaking Medicine News(10 mins):